Living donor liver transplantation for glycogen storage disease type Ib

Liver Transpl. 2009 Dec;15(12):1867-71. doi: 10.1002/lt.21929.

Abstract

Glycogen storage disease type 1b (GSD-1b) is due to an autosomal recessive inborn error of carbohydrate metabolism caused by defects in glucose-6-phosphatase translocase. Patients with GSD-1b have severe hypoglycemia with several clinical manifestations of hepatomegaly, obesity, a doll-like face, and neutropenia. Liver transplantation has been indicated for severe glucose intolerance. This study retrospectively reviewed 4 children with a diagnosis of GSD-1b who underwent living-donor liver transplantation (LDLT). Between November 2005 and June 2008, 96 children underwent LDLT with overall patient and graft survival of 92.3%. Of these, 4 (4.2%) were indicated for GSD-1b. All patients are doing well with an excellent quality of life because of the stabilization of glucose intolerance, decreased hospital admission, and normalized neutrophil count. LDLT appears to be a feasible option and is associated with a better quality of life for patients with GSD-1b. Long-term observation may be necessary to collect sufficient data to confirm the efficacy of this treatment modality.

MeSH terms

  • Adolescent
  • Child
  • Child, Preschool
  • Female
  • Glycogen Storage Disease Type I / complications
  • Glycogen Storage Disease Type I / mortality
  • Glycogen Storage Disease Type I / surgery*
  • Graft Survival
  • Hospitalization
  • Humans
  • Hypoglycemia / etiology
  • Hypoglycemia / prevention & control
  • Infant
  • Liver Transplantation* / adverse effects
  • Liver Transplantation* / mortality
  • Living Donors*
  • Male
  • Quality of Life
  • Retrospective Studies
  • Time Factors
  • Treatment Outcome